Skip to Main Content
Contribute Try STAT+ Today

Nearly two dozen lawmakers introduced identical bills in the House and Senate Wednesday that take a kitchen sink approach to tackling the rising cost of medicines, from allowing Medicare to negotiate prices to removing tax breaks that drug makers receive for advertising expenses.

Dubbed the Improving Access to Affordable Prescription Drugs Act, the legislation comes amid mounting controversy over prescription drug prices, a hot-button issue that has put the pharmaceutical industry on the defensive as a growing number of polls show Americans want the government to take action.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Appreciate efforts of Senators Franken and Sanders to lower drug prices, but why don’t they require those drugs and devices to also be labeled truthfully and not omit material risk and safety information when those products are often used off-label?

Comments are closed.